TORONTO - Cutera , Inc. (NASDAQ:CUTR), a prominent provider of aesthetic and dermatology solutions, announced today the release of xeo+, a multi-application laser and light-based platform. The new system integrates updated features and redesigned handpieces aimed at enhancing treatment efficiency and user experience in aesthetic practices.
The xeo+ builds on its predecessor's legacy, the original xeo introduced in 2003, which was notable for pioneering the Nd:YAG laser technology and the Laser Genesis™ skin revitalization treatment. The updated xeo+ platform boasts quicker treatment times, a user-friendly interface, and improved patient comfort through larger spot size options and advanced contact cooling.
Dr. Mira Kaga, founder of The Kaga Institute of Medicine and Aesthetics, shared her experience with the original xeo, emphasizing the efficiency and broadened treatment capabilities that xeo+ offers to her practice. The platform's versatility and ease of use make it accessible to providers with varying levels of expertise.
The xeo+ system is designed to address a wide array of aesthetic concerns, offering over 25 treatment solutions for skin revitalization, hair removal, vascular issues, and pigment reduction. This flexibility enables practices to expand their services and cater to a diverse patient demographic.
Currently available to physicians in the U.S. and Canada, xeo+ is positioned to meet the dynamic needs of modern aesthetic practices.
Cutera has made safety and risk information about xeo+ accessible to healthcare providers upon request. Patients considering treatments with xeo+ are advised to consult with their healthcare providers.
The announcement of xeo+ is based on a press release statement from Cutera, Inc.
InvestingPro Insights
As Cutera, Inc. (NASDAQ:CUTR) launches its innovative xeo+ platform, the company's financial health and market performance provide additional context for investors. Cutera operates with significant financial challenges, as indicated by a substantial debt burden. The company has also been experiencing a decline in sales, with revenue shrinking by -15.86% over the last twelve months as of Q1 2023. This is further reflected in the -26.45% quarterly revenue decline reported in Q1 2023.
On the market performance front, Cutera's stock price has been volatile, with a -94.35% one-year price total return as of early April 2024. Despite this, management has shown confidence in the company's future by aggressively buying back shares, which could be a positive signal for investors. However, the company's valuation implies a poor free cash flow yield, and analysts do not anticipate profitability this year.
For those considering an investment in Cutera, the company's market capitalization stands at a modest 34.93M USD. The price per share at the previous close was 1.61 USD, which is only 5.63% of its 52-week high, highlighting the significant drop in its stock price over the past year.
InvestingPro Tips suggest that while Cutera has liquid assets that exceed short-term obligations, indicating some level of financial stability, the overall picture is one of caution due to the company's performance and market trends. Investors interested in a deeper analysis of Cutera's financial and market position can find additional tips on InvestingPro. There are 15 more InvestingPro Tips available, which could provide further insights into whether Cutera's recent product launch could be a turning point for the company. Use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription for more detailed analytics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.